PATENT CLAIM ANALYSIS

Application Number: 16061279
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "259410"]

Abstract:
Disclosed in the present invention are a crystalline Form of pyrido[1,2-a]pyrimidone analog, a preparation method therefor and an intermediate thereof,

Claim (Index 28):
Crystalline forms of Compound I or the salts thereof of  claim 22 , wherein the salt is represented by the following formula Compound 2, characterized in that crystalline Form III of Compound 2 has diffraction peaks at 2\u03b8=6.979\u00b0, 9.939\u00b0, 14.397\u00b0, 16.107\u00b0, 20.982\u00b0, 25.990\u00b0 in a X-ray diffraction pattern.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.08333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15504018', '15539147', '16331915', '12559927', '16343165']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8082039235152002
- 35 USC 102 Novelty (BERT): 0.5246346579413321
- Combined Prediction Score: 0.7798469969578133
- Mean Citation Score: 323.776176
- Max Citation Score: 338.88705
- Similarity Product: 268.35351803471445

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test